Aprea Therapeutics, Inc. (APRE)Â
NASDAQ$2.39
Market Cap
$12.99M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
260 of 922
Rank in Industry
149 of 526
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
APRE Insider Trading Activity
APRE Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $165,941 | 9 | 90 |
Sells | $29,583 | 1 | 10 |
Related Transactions
| Duey Marc | director | 2 | $132,190 | 1 | $29,583 | $102,607 |
| Seizinger Bernd R. | director | 1 | $26,800 | 0 | $0 | $26,800 |
| Gilad Oren | President/CEO | 4 | $5,654 | 0 | $0 | $5,654 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 2 | $1,298 | 0 | $0 | $1,298 |
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Insider Activity of Aprea Therapeutics, Inc.
Over the last 12 months, insiders at Aprea Therapeutics, Inc. have bought $165,941 and sold $29,583 worth of Aprea Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aprea Therapeutics, Inc. have bought $162,430 and sold $31.43M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Duey Marc (director) — $132,190. Seizinger Bernd R. (director) — $26,800. Gilad Oren (President/CEO) — $5,654.
The last purchase of 500 shares for transaction amount of $1,958 was made by Gilad Oren (President/CEO) on 2024‑10‑23.
List of Insider Buy and Sell Transactions, Aprea Therapeutics, Inc.
| 2024-10-23 | Gilad Oren | President/CEO | 500 0.0086% | $3.92 | $1,958 | -13.59% | ||
| 2024-10-18 | Sale | Duey Marc | director | 6,462 0.1238% | $4.58 | $29,583 | -22.39% | |
| 2024-10-16 | Duey Marc | director | 30,000 0.8303% | $4.39 | $131,700 | -2.14% | ||
| 2024-10-15 | Gilad Oren | President/CEO | 250 0.0046% | $2.90 | $725 | +12.46% | ||
| 2024-10-14 | Gilad Oren | President/CEO | 1,000 0.0163% | $2.59 | $2,590 | +33.79% | ||
| 2024-10-14 | Duey Marc | director | 190 0.0031% | $2.58 | $490 | +33.79% | ||
| 2024-10-11 | Seizinger Bernd R. | director | 10,000 0.169% | $2.68 | $26,800 | +31.54% | ||
| 2024-10-11 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 50 0.0008% | $2.46 | $123 | +31.54% | ||
| 2024-10-10 | Gilad Oren | President/CEO | 150 0.0024% | $2.54 | $381 | +34.45% | ||
| 2024-10-10 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 450 0.0074% | $2.61 | $1,175 | +34.45% | ||
| 2024-03-13 | Gilad Oren | President, CEO | 2,000 0.0683% | $7.29 | $14,580 | -31.53% | ||
| 2024-03-13 | Seizinger Bernd R. | director | 6,860 0.2342% | $7.29 | $50,009 | -31.53% | ||
| 2024-03-13 | Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 1,010 0.0345% | $7.29 | $7,363 | -31.53% | ||
| 2024-03-13 | HENNEMAN JOHN B III | director | 6,860 0.2342% | $7.29 | $50,009 | -31.53% | ||
| 2023-06-07 | Seizinger Bernd R. | director | 6,029 0.1917% | $3.68 | $22,192 | +18.87% | ||
| 2023-06-06 | Seizinger Bernd R. | director | 4,068 0.1208% | $3.63 | $14,764 | +11.20% | ||
| 2020-12-28 | Sale | Redmile Group, LLC | 10 percent owner | 500,000 2.4014% | $5.58 | $2.79M | -11.73% | |
| 2020-10-05 | Sale | 5AM Ventures IV, L.P. | Former 10% holder | 175,000 0.7844% | $25.30 | $4.43M | -80.91% | |
| 2020-07-07 | Sale | KDev Investments AB | 10 percent owner | 241,703 1.1593% | $34.55 | $8.35M | -79.65% | |
| 2020-06-16 | Sale | ROCKLAGE SCOTT M | Former 10% holder | 120,164 0.5556% | $33.30 | $4M | -38.45% |
Total: 38
*Gray background shows transactions not older than one year
Insider Historical Profitability
30.38%
| Gilad Oren | President/CEO | 333395 6.1343% | $796,814.05 | 5 | 0 | <0.0001% |
| Duey Marc | director | 233651 4.2991% | $558,425.89 | 2 | 1 | |
| Seizinger Bernd R. | director | 44730 0.823% | $106,904.70 | 4 | 0 | <0.0001% |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr | 19368 0.3564% | $46,289.52 | 3 | 0 | <0.0001% |
| Christenson Johan | director | 2366104 43.5354% | $5.65M | 1 | 0 | +53.58% |
| HealthCap VII, L.P. | 10 percent owner | 2366104 43.5354% | $5.65M | 1 | 0 | +53.58% |
| KDev Investments AB | 10 percent owner | 1992586 36.6628% | $4.76M | 0 | 2 | |
| Redmile Group, LLC | 10 percent owner | 1768718 32.5437% | $4.23M | 1 | 1 | +53.58% |
| Versant Vantage I, L.P. | 10 percent owner | 333333 6.1332% | $796,665.87 | 1 | 0 | +53.58% |
| Versant V Luxco S.a r.l. | 10 percent owner | 333333 6.1332% | $796,665.87 | 1 | 0 | +53.58% |
| 5AM Ventures IV, L.P. | Former 10% holder | 138497 2.5483% | $331,007.83 | 1 | 4 | +53.58% |
| ROCKLAGE SCOTT M | Former 10% holder | 75965 1.3977% | $181,556.35 | 0 | 3 | |
| HENNEMAN JOHN B III | director | 8139 0.1498% | $19,452.21 | 2 | 0 | +11.02% |
| Magni Guido | director | 6500 0.1196% | $15,535.00 | 1 | 0 | +53.58% |
| SCHADE CHRISTIAN S | President & CEO | 5000 0.092% | $11,950.00 | 1 | 0 | +53.58% |
| Coiante Scott M | SVP, Chief Financial Officer | 2500 0.046% | $5,975.00 | 1 | 0 | +53.58% |
| Korbel Gregory Alan | VP of Business Dev't | 500 0.0092% | $1,195.00 | 1 | 0 | +53.58% |
| Attar Eyal C. | SVP, Chief Medical Officer | 200 0.0037% | $478.00 | 1 | 0 | +53.58% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$8,253,997 | 122 | -53.40% | $12.32M | |
$992,222,850 | 90 | -12.52% | $12.4M | |
$1,724,269 | 63 | -16.36% | $12.18M | |
$8,900,811 | 57 | -24.79% | $13.53M | |
$296,936 | 37 | -18.12% | $13.91M | |
$383,884 | 32 | -25.10% | $13.89M | |
$95,303,339 | 30 | -13.78% | $12.59M | |
$86,569,038 | 18 | -12.64% | $11.53M | |
$114,371,781 | 18 | -1.31% | $12.97M | |
$112,810,270 | 18 | -1.20% | $13.39M | |
Aprea Therapeutics, Inc. (APRE) | $29,469,413 | 18 | 30.38% | $12.99M |
$122,973 | 15 | -26.96% | $12.36M | |
$490,284 | 15 | -19.03% | $10.39M | |
$941,975 | 12 | -10.74% | $12.19M | |
$389,864 | 11 | 12.52% | $14.5M | |
$36,538,405 | 10 | -21.99% | $15.07M | |
$38,247,728 | 10 | -10.97% | $13.9M | |
$11,777,042 | 10 | -11.94% | $13.06M | |
$2,891,537 | 8 | -39.31% | $13.82M |
APRE Institutional Investors: Active Positions
| Increased Positions | 10 | +47.62% | 87,793 | +4.39% |
| Decreased Positions | 5 | -23.81% | 11,500 | -0.57% |
| New Positions | 5 | New | 64,455 | New |
| Sold Out Positions | <1 | Sold Out | 899 | Sold Out |
| Total Postitions | 26 | +23.81% | 2M | +3.81% |
APRE Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Aigh Capital Management Llc | $1,294.00 | 10.79% | 539,300 | 0 | 0% | 2024-12-31 |
| Sio Capital Management, Llc | $664.00 | 5.53% | 276,603 | 0 | 0% | 2024-12-31 |
| Sphera Funds Management Ltd. | $648.00 | 5.4% | 270,000 | 0 | 0% | 2024-12-31 |
| Nantahala Capital Management, Llc | $494.00 | 4.12% | 205,760 | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $417.00 | 3.48% | 173,842 | 0 | 0% | 2024-12-31 |
| Stonepine Capital Management, Llc | $358.00 | 2.98% | 149,221 | +12,047 | +8.78% | 2024-12-31 |
| Dafna Capital Management Llc | $329.00 | 2.74% | 137,174 | 0 | 0% | 2024-12-31 |
| Exome Asset Management Llc | $307.00 | 2.56% | 127,960 | -9,214 | -6.72% | 2024-12-31 |
| Geode Capital Management, Llc | $102.00 | 0.85% | 42,663 | +2,596 | +6.48% | 2024-12-31 |
| Morgan Stanley | $88.00 | 0.74% | 36,808 | +2,600 | +7.6% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.